News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Swedish Orphan Biovitrum Acquires Full Rights for Kineret® and Additional Clinical Data for Kepivance®From Amgen (AMGN)


9/9/2013 9:26:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that they have acquired the full rights to develop and commercialize Kineret (anakinra) from American biotechnology company Amgen for all therapeutic indications. The revised agreement builds on the previous agreement that gave Sobi rights for Kineret within the field of Rheumatoid arthritis (RA) and four orphan drug indications, including Cryopyrin Associated Periodic Syndrome (CAPS).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES